{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:33:57Z","timestamp":1783571637799,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>In this study, we analyzed a thiotepa\u2010based conditioning regimen for allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia, using the EBMT database. A total of 323 patients were identified. The median age was 43\u00a0years. Disease status at transplant was first complete remission (CR1) in 48.9%, CR2 in 21.7%, CR3 in 6.2%, while 23.2% of the patients had an active disease at the time of transplant. This was performed from a HLA\u2010matched sibling (49.8%) or a matched\u2010unrelated donor (51.2%). The incidence of acute graft\u2010vs.\u2010host disease (GvHD) (grade\u00a0&gt;\u00a0II) was 26.6%, while chronic GvHD occurred in 35.9% of the patients at 1\u00a0year (24.6% with extensive disease). With a median follow\u2010up of 16.8\u00a0months, the nonrelapse mortality was 12.4 and 25.3% at 100\u00a0days and 1\u00a0year, respectively. The relapse incidence at 1\u00a0year was 33.3% with no difference for patients in CR1 (27%). The one\u2010year leukemia\u2010free survival (LFS) and overall survival (OS) were 57 and 66%, respectively for the entire cohort and 50 and 66%, respectively in patients in CR1. Thiotepa\/busulfan\u00a0\u00b1\u00a0melphalan (<jats:italic>n<\/jats:italic>\u00a0=\u00a0213) in comparison to thiotepa\/other (<jats:italic>n<\/jats:italic>\u00a0=\u00a0110) conditioning regimen resulted in higher relapse incidence at 1\u00a0year (34.9 vs. 30.3%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.016) and lower LFS (38.8 vs. 45.9%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0203), while nonrelapse mortality (23.8 vs. 26.3%, n.s.) and OS (59.6 vs. 51.1%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.109) did not differ. This large study suggests that a thiotepa\u2010based conditioning for allogeneic transplantation in acute lymphoblastic leukemia is feasible and effective, with the main outcomes being comparable to those achieved with other regimens. Am. J. Hematol. 92:18\u201322, 2017. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24567","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T23:16:24Z","timestamp":1475018184000},"page":"18-22","source":"Crossref","is-referenced-by-count":11,"title":["Thiotepa\u2010based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia\u2014A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1002","volume":"92","author":[{"given":"Sandra","family":"Eder","sequence":"first","affiliation":[{"name":"EBMT Office Paris, H\u00f4pital Saint\u2010Antoine Paris France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Beohou","sequence":"additional","affiliation":[{"name":"EBMT Office Paris, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[{"name":"EBMT Office Paris, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda Hospital Universitari i polit\u00e8cnic La Fe Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology University Medical Center Freiburg Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Arcese","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplant University of Rome \u2018Tor Vergata\u2019 Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Or","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Hadassah University Hospital Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[{"name":"S.Orsola\u2010Malpighi Hospital Institute of Hematology and Medical, Oncology L and A Ser\u00e0gnoli, Bologna University Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"Oncology (Section of Adult Haematolgy\/BMT), King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology, BMT Hospital St. Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"Hematology University Hospital Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[{"name":"EBMT Office Paris, H\u00f4pital Saint\u2010Antoine Paris France"},{"name":"Gliwice Branch Maria Sklodowska\u2010Curie Memorial Cancer Center and Institute of Oncology Gliwice Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"EBMT Office Paris, H\u00f4pital Saint\u2010Antoine Paris France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint\u2010Antoine Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"EBMT Office Paris, H\u00f4pital Saint\u2010Antoine Paris France"},{"name":"Hematology Division Chaim Sheba Medical Center and Tel Aviv University Tel\u2010Hashomer Ramat\u2010Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051761"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.027862"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400019917"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_8_6_1","first-page":"1131375","article-title":"Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no\u2010donor comparison","author":"Cornelissen JJ","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269571"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11960"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-266551"},{"key":"e_1_2_8_10_1","first-page":"2340","article-title":"N,N\u2032,N\u2033\u2010triethylenethiophosphoramide (thio\u2010TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450\u2010inducing agents","volume":"51","author":"Ng SF","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_8_11_1","first-page":"1605","article-title":"Toxicity, antitumor activity, and pharmacokinetics of spin\u2010labeled thiotepa analogs","volume":"6","author":"Emanuel NM","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_8_12_1","first-page":"911","article-title":"A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma","volume":"17","author":"Kamani N","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_13_1","first-page":"157","article-title":"Tandem high\u2010dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer","volume":"17","author":"Bitran JD","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02123.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701103"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood.V88.1.353.353","article-title":"Van Lint MT, Valbonesi M, et al. Thiotepa cyclophosphamide followed by granulocyte colony\u2010stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia","volume":"88","author":"Bacigalupo A","year":"1996","journal-title":"Blood"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00112-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.75"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704717"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705863"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702719"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.001"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.13"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.259"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12553"},{"key":"e_1_2_8_27_1","unstructured":"MED\u2010AB FORMS MANUAL. A Guide to the completion of the EBMT HSCT Med\u2010AB Forms EBMT 2010(2016 All rights reserved)."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705221"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.02.016"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.05.001"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.239"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24567","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T01:56:53Z","timestamp":1695002213000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1002\/ajh.24567"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24567","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]}}}